Novo Nordisk/DKr NOVO B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Novo Nordisk
Novo Nordisk A/S is a global healthcare company specializing in diabetes care and hormone replacement therapies. Headquartered in Bagsværd, Denmark, the company is renowned for its insulin and GLP-1 receptor agonists for treating diabetes, as well as products for obesity care and growth hormone therapy. Established in 1923, Novo Nordisk has grown its presence worldwide, operating in numerous countries with a substantial workforce. The company leverages its scientific research capabilities to maintain a strong position in the biopharmaceutical industry, focusing heavily on innovation in chronic disease management. Its integrated supply and production facilities support its strategic emphasis on quality control and sustainable production practices.
- Ticker
- DKr NOVO B
- Sector
- Health
- Primary listing
- CSE
- Employees
- 66,700
- Headquarters
- Bagsvaerd, Denmark
- Website
- www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
kr 1.1T
9.94
kr 26.20
0.35
kr 11.70
4.49%
Price and volume
Market cap
kr 1.1T
Beta
0.35
52-week high
kr 409.95
52-week low
kr 224.25
Average daily volume
5.4M
Dividend rate
kr 11.70
Financial strength
Current ratio
0.873
Quick ratio
0.642
Long term debt to equity
0.55
Total debt to equity
0.633
Dividend payout ratio (TTM)
44.64%
Interest coverage (TTM)
1,566.84%
Profitability
EBITDA (TTM)
173,677
Gross margin (TTM)
81.99%
Net profit margin (TTM)
35.35%
Operating margin (TTM)
48.99%
Effective tax rate (TTM)
21.72%
Revenue per employee (TTM)
kr 4,940,000
Management effectiveness
Return on assets (TTM)
18.73%
Return on equity (TTM)
59.82%
Valuation
Price to earnings (TTM)
9.944
Price to revenue (TTM)
3.511
Price to book
5.19
Price to tangible book (TTM)
11.58
Price to free cash flow (TTM)
24.206
Free cash flow yield (TTM)
4.13%
Free cash flow per share (TTM)
10.762
Dividend yield (TTM)
4.49%
Growth
Revenue change (TTM)
5.61%
Earnings per share change (TTM)
4.98%
3-year revenue growth (CAGR)
17.84%
10-year revenue growth (CAGR)
11.56%
3-year earnings per share growth (CAGR)
20.74%
10-year earnings per share growth (CAGR)
14.01%
3-year dividend per share growth (CAGR)
18.26%
10-year dividend per share growth (CAGR)
9.55%
Bulls say / Bears say
The Wegovy pill is gaining traction: Novo reported more than five million US prescriptions since launch, with weekly pill prescriptions above 265,000. Wider overseas launches could extend that growth. (SEC)
Recent trading has improved: second-quarter adjusted sales rose 7% and adjusted operating profit rose 11% at constant exchange rates. Novo also tightened its 2026 outlook to flat-to-down 6% growth, from a previous forecast of down 4% to down 12%. (SEC)
CagriSema offers a potential next product: its Phase 3 diabetes trials met their main blood-sugar endpoints and confirmed weight-loss benefits. That could broaden Novo’s offering beyond existing semaglutide products if the candidate reaches market. (Novo Nordisk)
Eli Lilly is a formidable rival: its Zepbound and Mounjaro sales surged in the second quarter, widening the gap with Novo in obesity and diabetes medicines. That makes it harder for Novo to regain market share. (Reuters)
Pricing is weighing on the outlook: Novo expects 2026 adjusted sales and operating profit to be flat or fall by as much as 6%. The company cites lower realised prices, US market-access deals and weaker coverage alongside competition. (SEC)
Novo remains heavily exposed to semaglutide, with patent expiries looming in the early 2030s for the active ingredient in Wegovy and Ozempic. Investors have pressed management for a clearer growth plan beyond that franchise. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Upcoming events
No upcoming events
Funds containing Novo Nordisk
AllEURUSD
Fund name | Fund size | DKr NOVO B weighting |
|---|---|---|
Xtrackers MSCI Nordic£XDN0 | €1.1B | 8.52% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 6.66% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 6.66% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 6.34% |
iShares STOXX Europe 50€EXW3 | €141M | 2.75% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.